157 related articles for article (PubMed ID: 1431886)
21. Design, synthesis and antimalarial activity of a new class of iron chelators.
Solomon VR; Haq W; Puri SK; Srivastava K; Katti SB
Med Chem; 2006 Mar; 2(2):133-8. PubMed ID: 16787362
[TBL] [Abstract][Full Text] [Related]
22. Iron chelation with desferrioxamine B in adults with asymptomatic Plasmodium falciparum parasitemia.
Gordeuk VR; Thuma PE; Brittenham GM; Zulu S; Simwanza G; Mhangu A; Flesch G; Parry D
Blood; 1992 Jan; 79(2):308-12. PubMed ID: 1730079
[TBL] [Abstract][Full Text] [Related]
23. Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria.
Mohanty D; Ghosh K; Pathare AV; Karnad D
Indian J Med Res; 2002 Jan; 115():17-21. PubMed ID: 12424933
[TBL] [Abstract][Full Text] [Related]
24. Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures.
Loyevsky M; Sacci JB; Boehme P; Weglicki W; John C; Gordeuk VR
Exp Parasitol; 1999 Feb; 91(2):105-14. PubMed ID: 9990337
[TBL] [Abstract][Full Text] [Related]
25. Mode of action of iron(III) chelators as antimalarials. III. Overadditive effects in the combined action of hydroxamate-based agents on in vitro growth of Plasmodium falciparum.
Tsafack A; Golenser J; Libman J; Shanzer A; Cabantchik ZI
Mol Pharmacol; 1995 Feb; 47(2):403-9. PubMed ID: 7870051
[TBL] [Abstract][Full Text] [Related]
26. Iron chelation therapy for malaria: a review.
Mabeza GF; Loyevsky M; Gordeuk VR; Weiss G
Pharmacol Ther; 1999 Jan; 81(1):53-75. PubMed ID: 10051178
[TBL] [Abstract][Full Text] [Related]
27. In vivo antimalarial action of a lipophilic iron (III) chelator: suppression of Plasmodium vinckei infection by reversed siderophore.
Lytton SD; Loyevsky M; Mester B; Libman J; Landau I; Shanzer A; Cabantchik ZI
Am J Hematol; 1993 Jul; 43(3):217-20. PubMed ID: 8352239
[TBL] [Abstract][Full Text] [Related]
28. The biochemical basis for the selective antimalarial action of iron chelators on Plasmodium falciparum parasitized cells.
Lytton SD; Loyevsky M; Libman J; Mester B; Shanzer A; Cabantchik ZI
Adv Exp Med Biol; 1994; 356():385-97. PubMed ID: 7887244
[No Abstract] [Full Text] [Related]
29. Iron chelating agents for treating malaria.
Smith HJ; Meremikwu M
Cochrane Database Syst Rev; 2000; 2003(2):CD001474. PubMed ID: 10796645
[TBL] [Abstract][Full Text] [Related]
30. Basic 3-hydroxypyridin-4-ones: potential antimalarial agents.
Dehkordi LS; Liu ZD; Hider RC
Eur J Med Chem; 2008 May; 43(5):1035-47. PubMed ID: 17869385
[TBL] [Abstract][Full Text] [Related]
31. Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: studies in rat heart cells in culture.
Hershko C; Link G; Pinson A; Peter HH; Dobbin P; Hider RC
Blood; 1991 May; 77(9):2049-53. PubMed ID: 2018841
[TBL] [Abstract][Full Text] [Related]
32. Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores.
Zevin S; Link G; Grady RW; Hider RC; Peter HH; Hershko C
Blood; 1992 Jan; 79(1):248-53. PubMed ID: 1728313
[TBL] [Abstract][Full Text] [Related]
33. Protective activity of biflavanones from Garcinia kola against Plasmodium infection.
Konziase B
J Ethnopharmacol; 2015 Aug; 172():214-8. PubMed ID: 26129936
[TBL] [Abstract][Full Text] [Related]
34. Iron chelation therapy for malaria.
Gordeuk VR; Thuma PE; Brittenham GM
Adv Exp Med Biol; 1994; 356():371-83. PubMed ID: 7887243
[No Abstract] [Full Text] [Related]
35. Differential cytotoxicity of iron chelators on malaria-infected cells versus mammalian cells.
Glickstein H; Breuer W; Loyevsky M; Konijn AM; Shanzer A; Cabantchik ZI
Blood; 1996 Jun; 87(11):4871-8. PubMed ID: 8639861
[TBL] [Abstract][Full Text] [Related]
36. Effect of orally active hydroxypyridinone iron chelators on human lymphocyte function.
Pattanapanyasat K; Webster HK; Tongtawe P; Kongcharoen P; Hider RC
Br J Haematol; 1992 Sep; 82(1):13-9. PubMed ID: 1419787
[TBL] [Abstract][Full Text] [Related]
37. Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant.
Porter JB; Gyparaki M; Burke LC; Huehns ER; Sarpong P; Saez V; Hider RC
Blood; 1988 Nov; 72(5):1497-503. PubMed ID: 3179437
[TBL] [Abstract][Full Text] [Related]
38. The combined effect of iron chelators and classical antimalarials on the in-vitro growth of Plasmodium falciparum.
van Zyl RL; Havlik I; Monteagudo FS
J Antimicrob Chemother; 1992 Sep; 30(3):273-8. PubMed ID: 1452491
[TBL] [Abstract][Full Text] [Related]
39. The treatment of animal models of malaria with iron chelators by use of a novel polymeric device for slow drug release.
Golenser J; Domb A; Teomim D; Tsafack A; Nisim O; Ponka P; Eling W; Cabantchik ZI
J Pharmacol Exp Ther; 1997 Jun; 281(3):1127-35. PubMed ID: 9190845
[TBL] [Abstract][Full Text] [Related]
40. Iron chelators: mode of action as antimalarials.
Cabantchik ZI; Glickstein H; Golenser J; Loyevsky M; Tsafack A
Acta Haematol; 1996; 95(1):70-7. PubMed ID: 8604590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
